MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics
Myriad Genetics guided to adjusted gross margin of 68%-69% for 2026. Months later, the Company cut its revenue outlook, suspended EBITDA guidance, and MYGN shareholders absorbed the loss. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Myriad Genetics (NASDAQ: MYGN) investors are sitting on losses...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.